castlebiosciences产品代理
castlebiosciences产品代理
Castle Biosciences 开发和商业化皮肤癌的诊断和预后测试。我们的测试提供临床可操作的肿瘤特异性基因组信息，以实现更准确的治疗计划决策。我们认为，单独使用临床和病理因素制定皮肤癌治疗计划的传统方法是不够的，可以通过结合个性化基因组信息来改进。
我们的 DecisionDx 测试提供个性化、临床可操作的信息，以帮助医疗保健提供者和患者对其治疗计划做出更明智的决定。我们的侵袭性皮肤黑色素瘤检测，DecisionDx®-黑色素瘤，是一种专有的基因表达谱或 GEP，检测可以更准确地预测患者的转移或复发风险以及前哨淋巴结阳性。 DecisionDx®-SCC 是我们的 GEP 测试，可预测具有一种或多种风险因素的皮肤鳞状细胞癌患者的转移风险。 DecisionDx®-UM 是葡萄膜黑色素瘤分期的护理标准，是我们的 GEP 测试，可预测葡萄膜黑色素瘤（一种罕见的眼癌）患者的转移风险。我们的综合诊断产品利用了 myPath 黑色素瘤和 DecisionDx® DiffDx™-黑色素瘤的优势。这些基因表达谱测试旨在提供高度准确的客观结果，以帮助皮肤病理学家和皮肤科医生表征难以诊断的黑色素细胞病变。
Innovators in Diagnostic and Prognostic Tests for Dermatologic Cancers
Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Our tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate, and can be improved by incorporating personalized genomic information.
Our DecisionDx tests provide personalized, clinically actionable information to help healthcare providers and patients make more informed decisions about their treatment plans. Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile, or GEP, test that more accurately predicts a patient’s risk of metastasis or recurrence as well as sentinel lymph node positivity. DecisionDx®-SCC is our GEP test that predicts the risk of metastasis for patients with cutaneous squamous cell carcinoma who have one or more risk factors. DecisionDx®-UM, the standard of care in
uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Our comprehensive diagnostic offering leverages the strengths of myPath Melanoma and DecisionDx® DiffDx™-Melanoma. These gene expression profile tests are designed to provide a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing difficult-to-diagnose melanocytic lesions.
We also have active research and development programs for tests in other dermatologic diseases with high clinical need.
All of our tests are performed in a CLIA-certified, CAP-accredited clinical laboratory. Our laboratory is licensed to perform tests throughout the U.S., and proprietary genomic tests have been separately approved by the New York State Department of Health.
